2 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.Advanced Breast Cancer; ER-positive Breast Cancer; ESR1 Gene Mutation; HER2-negative Breast CancerRecruitingPhase 32026-08-24NCT06382948
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA StudyArterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, peripheral arterial disease, peripheral vascular disease, vascular disorderActive, not recruitingNot applicable2025-09-23NCT04776434